Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersScience in Renal Medicine
You have accessRestricted Access

Vasculature and Kidney Complications in Sickle Cell Disease

Karl A. Nath and Zvonimir S. Katusic
JASN May 2012, 23 (5) 781-784; DOI: https://doi.org/10.1681/ASN.2011101019
Karl A. Nath
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zvonimir S. Katusic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Recent developments in sickle cell disease include the concept of a vasculopathic state and the classification of sickle cell disease into a hemolysis-endothelial dysfunction phenotype or a viscosity-vasoocclusion phenotype. The hemolysis-endothelial dysfunction phenotype largely reflects deficiency of or resistance to nitric oxide. In addition to discussing these areas, we suggest that the hemolysis-endothelial dysfunction phenotype also reflects the instability of sickle hemoglobin, the release of heme, and the induction of heme oxygenase-1. From these perspectives the renal complications of sickle cell disease are discussed and classified.

A century ago, James Herrick described sickle-shaped red blood cells (RBCs) in a West Indian dental student presenting with fever, leg ulcers, and respiratory symptoms.1 This misshaping of RBCs not only named the condition as sickle cell disease (SCD) and gave it an icon, but has long been regarded as a fundamental contributor to vasoocclusive disease: sickle RBCs, compromised rheologically because of polymerization of sickle hemoglobin, create a vascular logjam, thereby leading to vasoocclusion.

SCD is now recognized as involving not just vasoocclusion but also a plethora of pathogenetic processes categorized under the following rubrics: ischemia-reperfusion injury, inflammation, hemolysis, a procoagulant state, oxidative stress, nitric oxide (NO) deficiency, endothelial activation, aberrant vascular reactivity, and sympathetic-parasympathetic imbalance.2–4 These processes broadly interact, and any one may be influenced by others. A challenging issue is understanding the hierarchical construct that integrates these myriad pathways, linking them back to the aberrant behavior of sickle hemoglobin, and appraising their relative importance in SCD.

Vasculopathy in SCD

Studies by us and others more than a decade ago demonstrated the existence of endothelial dysfunction in murine models of SCD, a finding also observed in human SCD.3,5,6 These observations were a prelude to the concept of SCD as a vasculopathic disease,2 a perspective now widely accepted for the following reasons:4,7–9 It identifies a nexus for all other pathogenetic pathways; it helps explain the clinical manifestations of SCD, especially pulmonary hypertension, priapism, leg ulcers, and stroke (complications that may be associated with vascular histologic lesions); and it emphasizes the role of the interface between circulating blood and resident tissue in mediating disease, one to which therapies may be directed.

Classic risk factors for vascular disease—specifically, hypercholesterolemia, hyperlipidemia, hyperglycemia, and hypertension—cannot explain the development of vasculopathy in SCD.2,7,8 Patients with SCD do, however, exhibit systemic inflammation: Plasma levels of diverse inflammation-related molecules (IL-1, IL-8, monocyte chemoattractant protein-1, TNF-α, and endothelin-1) are elevated, whereas circulating leukocytes are increased and activated, and predict morbidity in SCD. Such an inflammatory milieu promotes endothelial activation, which can instigate inflammatory and procoagulant processes in the vasculature leading to vasculopathy. The procoagulant setting of SCD may also predispose to vasculopathy, and such molecules as tissue factor and plasminogen activator inhibitor-1, which are both procoagulant and proinflammatory, are substantially upregulated.

Endothelial generation of NO in the healthy vasculature exerts vasorelaxant, anti-inflammatory, and antithrombotic effects, and thus deficiency of or resistance to NO that occurs in SCD may underlie the vasculopathy.3,4,7–9 Deficiency of NO may be due to the following: NO scavenging by the heme group of sickle hemoglobin released into plasma by lysed RBCs; NO scavenging by vascular superoxide anion; depletion of plasma arginine by arginase released by lysed RBCs; and the effect of endogenous NOS inhibitors. Oxidative stress in SCD also inactivates tetrahydrobiopterin, a NOS cofactor, thereby uncoupling endothelial NO synthase such that superoxide anion, rather than NO, is produced. In certain settings vascular reactivity to NO is blunted.3,5

NO deficiency is a salient consideration in the classification of SCD into the hemolysis-endothelial dysfunction or the viscosity-vasoocclusion phenotypes.4,7–9 Such a distinction draws on the clinical observation that chronic organ injury in SCD may not correlate with vasoocclusive disease and emphasizes the increased likelihood of a vasculopathy occurring in the hemolysis-endothelial dysfunction phenotype.

Vasculopathies are manifest not only structurally but also functionally, and vascular behavior in SCD is abnormal in several ways.3 First, in contrast to the hypoperfusion of vasooccluded microcirculatory beds, hyperperfusion occurs in the systemic circulation in SCD: Systemic vascular resistances are decreased, cardiac output is increased, and there is enhanced perfusion in certain organs, particularly the kidneys, and in certain regional beds, such as the forearm. Indeed, patients with SCD without CKD exhibit lower systemic BP than healthy controls.

Second, certain vascular beds in steady state exhibit an upregulation of both vasoconstrictor and vasodilator species whose countervailing actions determine net perfusion; vasodilator systems, already upregulated in steady state, may not adequately counter additional vasoconstrictive stress during painful episodes, thereby incurring vascular instability.3

Third, in several settings, the vasculature in SCD exhibits increased sensitivity to vasoconstrictor species, including α1-adrenergic agonists10 and endothelin-1.11

Finally, SCD exhibits an abnormal response to shear stress.6,12 Shear stress is a fundamental determinant of vascular behavior: High laminar shear stress is vasoprotective by promoting the endothelial generation of NO, in part through the transcription factor KLF2; low laminar and oscillatory shear stresses are vasculopathic through proinflammatory transcription factors. We have recently demonstrated that there is an exaggerated response to vasculopathic shear stress in a murine model of SCD,12 whereas clinical observations in human SCD demonstrate impaired responses to shear stress6 and suggest that decreased KLF2 expression correlates with an increased risk for stroke in SCD.13

Vasculature and Kidney Disease in SCD

Patients with SCD exhibit recurrent episodes of hematuria and tubular abnormalities, such as a concentrating defect, impaired potassium excretion, and an acidification defect. Some 70% of patients may exhibit microalbuminuria, and 26% of adult patients develop CKD, the latter increased with aging.14–16 Of interest, the prevalence of sickle trait is high in African-American patients undergoing renal replacement therapy.17

These manifestations may reflect an abnormality in vascular perfusion or behavior. For example, recurrent bouts of hematuria and tubular dysfunction arise from medullary ischemia due to sludging of RBCs in the vasa recta; such sludging occurs because of hypoxia, hypertonicity, and acidosis in the medullary environment, along with its relatively low blood flow.

In contrast to hypoperfusion of the medulla, in SCD the cortex is often hyperperfused because of decreased renal vascular resistance. This increased blood flow is attended by increased GFR. Hyperperfusion of the kidney promotes glomerulomegaly, the latter, in certain settings, presaging glomerulosclerosis.18 Glomerulosclerosis, the most common glomerulopathy in SCD, also probably reflects hemodynamically mediated glomerular damage by hyperfiltration; hyperfiltration is a risk factor for proteinuria and CKD in SCD. Furthermore, hyperfiltration increases the filtered sodium load and tubular reabsorption of sodium, thereby augmenting renal oxygen consumption. Such hypermetabolism promotes tubulointerstitial injury through oxidative stress and other mechanisms.19 This effect could prove particularly damaging when there are increased renal deposits of iron, as occurs in SCD.

Hemolysis is also a risk factor for hyperfiltration, proteinuria, and CKD in SCD,20–23 and complications of SCD, such as pulmonary hypertension, which are strongly associated with hemolysis and vasculopathy, are risk factors for CKD.24,25 That hemolysis is associated with hyperfiltration seems quite puzzling because hemolysis commonly induces a renal vasoconstrictive state (NO scavenging by hemoglobin), whereas hyperfiltration is often attended by hyperperfusion in SCD.

We propose that in SCD, hemolysis per se can induce vasodilation, either regionally or systemically, because of the unstable nature of sickle hemoglobin. Such instability leads to the release of heme and the induction of heme oxygenase-1, the latter exerting vasorelaxant effects through the generation of carbon monoxide and oxidant-scavenging actions. In support of this are prior studies demonstrating increased plasma levels of heme in SCD26 and our observations that heme oxygenase-1 is robustly induced in the endothelium and smooth muscle cells in renal arteries in human SCD.27 Heme itself is proinflammatory, inducing, for example, the vasculopathic chemokine, monocyte chemoattractant protein-1,28,29 and may thus promote vascular injury.28–30 Finally, the trafficking of heme across the glomerular filtration barrier exposes the endothelia and podocytes to a metabolite with cytotoxic and proapoptotic effects,28,31 thereby impairing glomerular permselectivity and causing proteinuria.

On the basis of these considerations, Figure 1 expands the hemolysis-endothelial dysfunction phenotype in the kidney to include the downstream effects resulting from the release of heme from sickle hemoglobin, and Table 1 categorizes the kidney complications of SCD according to this modified classification.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Modified hemolysis-endothelial dysfunction phenotype and proposed renal pathophysiology in human SCD. Hemolysis in human SCD leads to NO scavenging by plasma hemoglobin (HbSS) and increased amounts of heme because of the instability of sickle hemoglobin. Heme is cytotoxic, thereby injuring glomerular cells and causing proteinuria and CKD. Induction of heme oxygenase-1, through the generation of carbon monoxide and other actions, induces vasodilation, and thus promotes hyperfiltration. The minus sign signifies that induction of heme oxygenase-1 can mitigate the adverse effects of heme by degrading heme and other cytoprotective effects of heme oxygenase-1.

View this table:
  • View inline
  • View popup
Table 1.

Classification of renal manifestations of SCD based on described phenotypes

The viscosity-vasoocclusive phenotype, normally confined to the medulla, may extend into the cortex after renal stress, and such extension is accompanied by pronounced reductions in renal blood flow and GFR.32,33 That such extension also occurs in human SCD is supported by the occurrence of acute kidney injury during intercurrent illnesses in patients with SCD,34 reductions in renal blood flow during painful episodes,35 and histologic documentation of cortical vascular congestion in patients with SCD who have acute kidney injury.36,37

Conclusions

SCD is a chronic disease punctuated by acute insults that target, among others, the vasculature and its endothelium; SCD is also characterized by adverse, long-range signaling to distant organs and tissues from seemingly contained insults. Both considerations are relevant to the kidney in SCD.

As is now clear from studies of acute kidney injury, renal ischemia induces renal endothelial cell loss and endothelial-mesenchymal transition, effects that contribute to the increased risk for CKD after ischemic acute kidney injury.38 We suggest that episodic injury to the glomerular and cortical capillaries, caused by vasoocclusive and other insults, may contribute to CKD in SCD.

Events originating elsewhere in patients with SCD can target the kidney, and the kidney, in turn, can engage in long-range signaling to distant organs and tissues. Ischemia localized to one kidney, for example, can induce glomerular and cortical capillary congestion in the intact, contralateral kidney, and ischemia localized to both kidneys can induce vascular congestion and sickling in pulmonary capillaries.32 Such action-at-a-distance of kidney injury in SCD, channeled through the vasculature, may thereby contribute to the morbidity of SCD.

Disclosures

None.

Acknowledgments

We thank Tammy Engel for her secretarial expertise.

These studies were supported by National Institutes of Health Grants DK47060, HL-55552, and HL-91867.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • Copyright © 2012 by the American Society of Nephrology

References

  1. ↵
    1. Herrick JB
    : Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910. Yale J Biol Med 74: 179–184, 2001pmid:11501714
    OpenUrlPubMed
  2. ↵
    1. Hebbel RP,
    2. Osarogiagbon R,
    3. Kaul D
    : The endothelial biology of sickle cell disease: Inflammation and a chronic vasculopathy. Microcirculation 11: 129–151, 2004pmid:15280088
    OpenUrlCrossRefPubMed
  3. ↵
    1. Nath KA,
    2. Katusic ZS,
    3. Gladwin MT
    : The perfusion paradox and vascular instability in sickle cell disease. Microcirculation 11: 179–193, 2004pmid:15280091
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kato GJ,
    2. Gladwin MT,
    3. Steinberg MH
    : Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 21: 37–47, 2007pmid:17084951
    OpenUrlCrossRefPubMed
  5. ↵
    1. Nath KA,
    2. Shah V,
    3. Haggard JJ,
    4. Croatt AJ,
    5. Smith LA,
    6. Hebbel RP,
    7. Katusic ZS
    : Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol 279: R1949–R1955, 2000pmid:11080057
    OpenUrlPubMed
  6. ↵
    1. Belhassen L,
    2. Pelle G,
    3. Sediame S,
    4. Bachir D,
    5. Carville C,
    6. Bucherer C,
    7. Lacombe C,
    8. Galacteros F,
    9. Adnot S
    : Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 97: 1584–1589, 2001pmid:11238095
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Kato GJ,
    2. Hebbel RP,
    3. Steinberg MH,
    4. Gladwin MT
    : Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 84: 618–625, 2009pmid:19610078
    OpenUrlCrossRefPubMed
  8. ↵
    1. Morris CR
    : Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology (Am Soc Hematol Educ Program) 2008: 177–185, 2008pmid:19074078
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Wood KC,
    2. Hsu LL,
    3. Gladwin MT
    : Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radic Biol Med 44: 1506–1528, 2008pmid:18261470
    OpenUrlCrossRefPubMed
  10. ↵
    1. Juncos R,
    2. Juncos L,
    3. Hebbel RP,
    4. Vercellotti GM,
    5. Katusic ZS,
    6. Nath KA
    : Selective enhancement of contractions to α1-adrenergic receptor activation in the aorta of mice with sickle cell disease. J Cardiovasc Pharmacol 57: 263–266, 2011pmid:21107280
    OpenUrlCrossRefPubMed
  11. ↵
    1. Sabaa N,
    2. de Franceschi L,
    3. Bonnin P,
    4. Castier Y,
    5. Malpeli G,
    6. Debbabi H,
    7. Galaup A,
    8. Maier-Redelsperger M,
    9. Vandermeersch S,
    10. Scarpa A,
    11. Janin A,
    12. Levy B,
    13. Girot R,
    14. Beuzard Y,
    15. Leboeuf C,
    16. Henri A,
    17. Germain S,
    18. Dussaule JC,
    19. Tharaux PL
    : Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 118: 1924–1933, 2008pmid:18382768
    OpenUrlCrossRefPubMed
  12. ↵
    1. Kang L,
    2. Yamada S,
    3. Hernandez MC,
    4. Croatt AJ,
    5. Grande JP,
    6. Juncos JP,
    7. Vercellotti GM,
    8. Hebbel RP,
    9. Katusic ZS,
    10. Terzic A,
    11. Nath KA
    : Regional and systemic hemodynamic responses following the creation of a murine arteriovenous fistula. Am J Physiol Renal Physiol 301: F845–F851, 2011pmid:21697243
    OpenUrlCrossRefPubMed
  13. ↵
    1. Enenstein J,
    2. Milbauer L,
    3. Domingo E,
    4. Wells A,
    5. Roney M,
    6. Kiley J,
    7. Wei P,
    8. Hebbel RP
    : Proinflammatory phenotype with imbalance of KLF2 and RelA: Risk of childhood stroke with sickle cell anemia. Am J Hematol 85: 18–23, 2010pmid:19957349
    OpenUrlPubMed
  14. ↵
    1. Falk RJ,
    2. Jennette JC
    : Sickle cell nephropathy. Adv Nephrol Necker Hosp 23: 133–147, 1994pmid:8154349
    OpenUrlPubMed
    1. Saborio P,
    2. Scheinman JI
    : Sickle cell nephropathy. J Am Soc Nephrol 10: 187–192, 1999pmid:9890326
    OpenUrlFREE Full Text
  15. ↵
    1. Guasch A,
    2. Navarrete J,
    3. Nass K,
    4. Zayas CF
    : Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol 17: 2228–2235, 2006pmid:16837635
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Derebail VK,
    2. Nachman PH,
    3. Key NS,
    4. Ansede H,
    5. Falk RJ,
    6. Kshirsagar AV
    : High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol 21: 413–417, 2010pmid:20056747
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Hostetter TH
    : Hyperfiltration and glomerulosclerosis. Semin Nephrol 23: 194–199, 2003pmid:12704579
    OpenUrlCrossRefPubMed
  18. ↵
    1. Nath KA,
    2. Croatt AJ,
    3. Hostetter TH
    : Oxygen consumption and oxidant stress in surviving nephrons. Am J Physiol 258: F1354–F1362, 1990pmid:2337154
    OpenUrlPubMed
  19. ↵
    1. Gurkan S,
    2. Scarponi KJ,
    3. Hotchkiss H,
    4. Savage B,
    5. Drachtman R
    : Lactate dehydrogenase as a predictor of kidney involvement in patients with sickle cell anemia. Pediatr Nephrol 25: 2123–2127, 2010pmid:20517617
    OpenUrlCrossRefPubMed
    1. Haymann JP,
    2. Stankovic K,
    3. Levy P,
    4. Avellino V,
    5. Tharaux PL,
    6. Letavernier E,
    7. Grateau G,
    8. Baud L,
    9. Girot R,
    10. Lionnet F
    : Glomerular hyperfiltration in adult sickle cell anemia: A frequent hemolysis associated feature. Clin J Am Soc Nephrol 5: 756–761, 2010pmid:20185605
    OpenUrlAbstract/FREE Full Text
    1. Maier-Redelsperger M,
    2. Lévy P,
    3. Lionnet F,
    4. Stankovic K,
    5. Haymann J-P,
    6. Lefèvre G,
    7. Avellino V,
    8. Perol J-P,
    9. Girot R,
    10. Elion J
    : Strong association between a new marker of hemolysis and glomerulopathy in sickle cell anemia. Blood Cells Mol Dis 45: 289–292, 2010pmid:20833087
    OpenUrlCrossRefPubMed
  20. ↵
    1. Hirschberg R
    : Glomerular hyperfiltration in sickle cell disease. Clin J Am Soc Nephrol 5: 748–749, 2010pmid:20299367
    OpenUrlFREE Full Text
  21. ↵
    1. Ataga KI,
    2. Brittain JE,
    3. Moore D,
    4. Jones SK,
    5. Hulkower B,
    6. Strayhorn D,
    7. Adam S,
    8. Redding-Lallinger R,
    9. Nachman P,
    10. Orringer EP
    : Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: Potential role of soluble fms-like tyrosine kinase-1. Eur J Haematol 85: 257–263, 2010pmid:20491879
    OpenUrlCrossRefPubMed
  22. ↵
    1. Gordeuk VR,
    2. Sachdev V,
    3. Taylor JG,
    4. Gladwin MT,
    5. Kato G,
    6. Castro OL
    : Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol 83: 15–18, 2008pmid:17696198
    OpenUrlCrossRefPubMed
  23. ↵
    1. Reiter CD,
    2. Wang X,
    3. Tanus-Santos JE,
    4. Hogg N,
    5. Cannon RO 3rd,
    6. Schechter AN,
    7. Gladwin MT
    : Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8: 1383–1389, 2002pmid:12426562
    OpenUrlCrossRefPubMed
  24. ↵
    1. Nath KA,
    2. Grande JP,
    3. Haggard JJ,
    4. Croatt AJ,
    5. Katusic ZS,
    6. Solovey A,
    7. Hebbel RP
    : Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol 158: 893–903, 2001pmid:11238038
    OpenUrlCrossRefPubMed
  25. ↵
    1. Tracz MJ,
    2. Alam J,
    3. Nath KA
    : Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol 18: 414–420, 2007pmid:17229906
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Kanakiriya SK,
    2. Croatt AJ,
    3. Haggard JJ,
    4. Ingelfinger JR,
    5. Tang SS,
    6. Alam J,
    7. Nath KA
    : Heme: a novel inducer of MCP-1 through HO-dependent and HO-independent mechanisms. Am J Physiol Renal Physiol 284: F546–F554, 2003pmid:12556365
    OpenUrlCrossRefPubMed
  27. ↵
    1. Belcher JD,
    2. Beckman JD,
    3. Balla G,
    4. Balla J,
    5. Vercellotti G
    : Heme degradation and vascular injury. Antioxid Redox Signal 12: 233–248, 2010pmid:19697995
    OpenUrlCrossRefPubMed
  28. ↵
    1. Gonzalez-Michaca L,
    2. Farrugia G,
    3. Croatt AJ,
    4. Alam J,
    5. Nath KA
    : Heme: A determinant of life and death in renal tubular epithelial cells. Am J Physiol Renal Physiol 286: F370–F377, 2004pmid:14707007
    OpenUrlCrossRefPubMed
  29. ↵
    1. Nath KA,
    2. Grande JP,
    3. Croatt AJ,
    4. Frank E,
    5. Caplice NM,
    6. Hebbel RP,
    7. Katusic ZS
    : Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am J Pathol 166: 963–972, 2005pmid:15793278
    OpenUrlCrossRefPubMed
  30. ↵
    1. Juncos JP,
    2. Grande JP,
    3. Croatt AJ,
    4. Hebbel RP,
    5. Vercellotti GM,
    6. Katusic ZS,
    7. Nath KA
    : Early and prominent alterations in hemodynamics, signaling, and gene expression following renal ischemia in sickle cell disease. Am J Physiol Renal Physiol 298: F892–F899, 2010pmid:20107113
    OpenUrlCrossRefPubMed
  31. ↵
    1. Sklar AH,
    2. Perez JC,
    3. Harp RJ,
    4. Caruana RJ
    : Acute renal failure in sickle cell anemia. Int J Artif Organs 13: 347–351, 1990pmid:2379968
    OpenUrlPubMed
  32. ↵
    1. Guvenc B,
    2. Aikimbaev K,
    3. Unsal C,
    4. Akgul E,
    5. Akgul AE,
    6. Binokay F,
    7. Besena A
    : Renal vascular resistance in sickle cell painful crisis. Int J Hematol 82: 127–131, 2005pmid:16146844
    OpenUrlCrossRefPubMed
  33. ↵
    1. Kimmelsteil P
    : Vascular occlusion and ischemic infarction in sickle cell disease. Am J Med Sci 216: 11–19, 1948pmid:18877309
    OpenUrlCrossRefPubMed
  34. ↵
    1. al Ani O,
    2. Baqi N
    : Clinical quiz. Cortical infarction secondary to intravascular sickling in the renal cortex. Pediatr Nephrol 13: 267–268, 1999pmid:10353420
    OpenUrlPubMed
  35. ↵
    1. Basile DP,
    2. Friedrich JL,
    3. Spahic J,
    4. Knipe N,
    5. Mang H,
    6. Leonard EC,
    7. Changizi-Ashtiyani S,
    8. Bacallao RL,
    9. Molitoris BA,
    10. Sutton TA
    : Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol 300: F721–F733, 2011pmid:21123492
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 23 (5)
Journal of the American Society of Nephrology
Vol. 23, Issue 5
1 May 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Vasculature and Kidney Complications in Sickle Cell Disease
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vasculature and Kidney Complications in Sickle Cell Disease
Karl A. Nath, Zvonimir S. Katusic
JASN May 2012, 23 (5) 781-784; DOI: 10.1681/ASN.2011101019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Vasculature and Kidney Complications in Sickle Cell Disease
Karl A. Nath, Zvonimir S. Katusic
JASN May 2012, 23 (5) 781-784; DOI: 10.1681/ASN.2011101019
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Vasculopathy in SCD
    • Vasculature and Kidney Disease in SCD
    • Conclusions
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • Molecular Characterization of Membranous Nephropathy: Quo Vadis?
  • More than a Marker: Arginase-1 in Kidney Repair
  • Enabling Patient Choice: The “Deciding Not to Decide” Option for Older Adults Facing Dialysis Decisions
Show more Up Front Matters

Science in Renal Medicine

  • Regulatory T Cells in AKI
  • Defining the Signals that Constitute the Nephron Progenitor Niche
  • Mechanisms of Hypoxia Responses in Renal Tissue
Show more Science in Renal Medicine

Cited By...

  • Acute Kidney Injury among Black Patients with Sickle Cell Trait and Sickle Cell Disease
  • Kidney Function Decline among Black Patients with Sickle Cell Trait and Sickle Cell Disease: An Observational Cohort Study
  • Tubular Acidification Defect in Adults with Sickle Cell Disease
  • Sickle Cell Trait and the Risk of ESRD in Blacks
  • Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease
  • Medullary Microvascular Thrombosis and Injury in Sickle Hemoglobin C Disease
  • Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy
  • Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease
  • Cardiac arrest following acute puerperal uterine inversion
  • Prevalence and Progression of Chronic Kidney Disease in Adult Patients With Sickle Cell Disease
  • Beneficial effect of prolonged heme oxygenase 1 activation in a rat model of chronic heart failure
  • Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire